Sigma Healthcare Ltd (ASX: SIG) share price is now trading as part of one of the ASX's largest healthcare companies following the completed merger with Chemist Warehouse. For FY25, Sigma delivered revenue of $6 billion, up 82%, and normalised net profit after tax up 40% to $579 million.
What did Sigma Healthcare report in FY25?
- Revenue rose 82% to $6 billion for FY25
- Normalised EBIT increased 41% to $835 million
- Normalised net profit after tax (NPAT) up 40% to $579 million
- Pro-forma EBIT (for full year post-merger) of $903 million
- Net debt reduced to $752 million at year end
- Fully franked dividend of 1.3 cents per share paid (50–70% NPAT payout ratio)
What else do investors need to know?
The successful merger with Chemist Warehouse transformed Sigma into Australia's leading retail pharmacy franchisor and pharmaceutical wholesaler, now supporting nearly 900 franchise stores and servicing some 3,000 wholesale pharmacy customers. The combined entity's market value reached approximately $35 billion, ranking Sigma in the ASX top 20.
Sigma has upgraded its expected annual synergy benefits from the merger to $100 million by year four, reflecting better-than-expected integration progress. Continued strong cash flow and lower capital investment requirements have also aided rapid debt reduction, giving the business room for future growth.
What's next for Sigma Healthcare?
Looking ahead, Sigma plans ongoing store rollouts both in Australia and overseas, focussing on network growth consistent with historical trends. Management expects to continue growing 'own and exclusive' product ranges to support margins, while ensuring integration and operational synergies from the Chemist Warehouse merger are fully delivered.
First quarter FY26 trading remained strong, with Chemist Warehouse Network sales up 17.9% and like-for-like sales up 14.7%. The group is entering the Christmas period with strong momentum and a focus on executing integration initiatives.
Sigma Healthcare share price snapshot
Sigma Healthcare shares have surged 68% over the past year, far outpacing the S&P/ASX 200 Index (ASX: XJO) which has climbed around 8% over the same period.
